MannKind (MNKD) shares sink after the FDA issues a complete response letter requesting two...

|About: MannKind Corporation (MNKD)|By:, SA News Editor

MannKind (MNKD) shares sink after the FDA issues a complete response letter requesting two additional clinical trials for the company's Afrezza insulin inhaler. It's the FDA's second rejection of the product. MNKD -42.8% premarket. (PR)